Stabilis

Hydralazine hydrochloride



Kauppanimi

Apresoline	Kanada
Hydralazine	Espanja, Iso-Britannia, Yhdysvallat
Hydrapres	Espanja

Stabilius liuoksessa

PVC		0,2 mg/ml	25°C	?	1			2367

Tekijät, jotka vaikuttavat stabiliuteen

					2367
	PVC				1173
	pH = 3,5				957

Yhteensopivuus

	Hydralazine hydrochloride : 20 mg/ml Caffeine : 10 mg/ml	∅	3964
	Hydralazine hydrochloride		5062

		Hydralazine hydrochloride : 20 mg/ml	RL	4603
		Hydralazine hydrochloride		5062
		Hydralazine hydrochloride		2367
		Hydralazine hydrochloride : 20 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Hydralazine hydrochloride : 20 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Hydralazine hydrochloride : 20 mg/ml Dexmedetomidine : 100 µg/ml		4389
		Hydralazine hydrochloride : 0,2 mg/ml Dobutamine hydrochloride : 0,2 mg/ml		1221
		Hydralazine hydrochloride : 20 mg/ml Heparin sodium : 1 UI/ml		1228
		Hydralazine hydrochloride : 20 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Hydralazine hydrochloride : 20 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Hydralazine hydrochloride : 20 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Hydralazine hydrochloride : 20 mg/ml Meropenem : 50 mg/ml		4319
		Hydralazine hydrochloride N-acetylcysteine : 200 mg/ml	∅	3766
		Hydralazine hydrochloride : 1 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Hydralazine hydrochloride Nesiritide		5048
		Hydralazine hydrochloride : 1 mg/ml Nitroglycerin : 0.4 mg/ml		1049
		Hydralazine hydrochloride Pantoprazole sodium		2090
		Hydralazine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l		1228
		Hydralazine hydrochloride : 20 mg/ml Potassium chloride : 40 mEq/l	RL	1228
		Hydralazine hydrochloride : 20 mg/ml Propofol		660
		Hydralazine hydrochloride Theophylline		5054
		Hydralazine hydrochloride : 0.04 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057

Antotapa

Viitteet

	tyyppi	julkaisu
660	Lehti	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
957	Lehti	Halasi S, Nairn JG. Stability studies of hydralazine in aqueous solutions. J Parenter Sci Technol 1990 ; 44: 30-34.
1049	Lehti	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1057	Lehti	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1173	Lehti	Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 1981 ; 38: 1308-1314.
1221	Lehti	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1228	Lehti	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
2090	Lehti	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2233	Lehti	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2367	Lehti	Gupta V.D. Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion. Int J Pharm Compound 2005 ; 9, 5: 399-401.
3012	Lehti	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3408	Lehti	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3766	Lehti	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3964	Lehti	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	Lehti	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

4389	Lehti	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Lehti	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
5048	Laboratorio	NATRECOR® (nesiritide) lyophilized powder for intravenous use - Highlights of prescribing information. 2012
5054	Laboratorio	POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2018
5062	Laboratorio	Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion - Summary of Product Characteristics Updated 09-Sep-2024 ADVANZ Pharma 2024

Stabilis

Hydralazine hydrochloride



Vakaus lääkevalmisteen

		100 mg	Sorbitoli 70% 40g Metyyliparabeeni 65 mg Propyyliparabeeni 35 mg Propyleeniglykoli 10 g Aspartaami 50 mg Puhdistettu vesi >> 100 ml	5°C		30			2836
		1000 mg	Sorbitoli 70% 40g Metyyliparabeeni 65 mg Propyyliparabeeni 35 mg Propyleeniglykoli 10 g Aspartaami 50 mg Puhdistettu vesi >> 100 ml	5°C		30			2836
		600 mg ® = ?	SyrSpend SF PH4® >> 150 mL	2-8°C		30			4408
		600 mg ® = ?	SyrSpend SF PH4® >> 150 mL	20-25°C		30			4408
		480 mg ®= (Rugby Laboratories)	OraPlus® / OraSweet® (1:1) >> 120 ml	5°C		24			2422
		480 mg ®= (Rugby Laboratories)	OraPlus® / OraSweet SF® (1:1) >> 120 m	5°C		48			2422

		100 mg	Sorbitoli 70% 40g Metyyliparabeeni 65 mg Propyyliparabeeni 35 mg Propyleeniglykoli 10 g Aspartaami 50 mg Puhdistettu vesi >> 100 ml	5°C		30			2836
		1000 mg	Sorbitoli 70% 40g Metyyliparabeeni 65 mg Propyyliparabeeni 35 mg Propyleeniglykoli 10 g Aspartaami 50 mg Puhdistettu vesi >> 100 ml	5°C		30			2836

Tekijät, jotka vaikuttavat stabiliuteen

					2422
	EDTA				3168
	Glukoosi				3168
	Natriumbisulfiitti				3168

Viitteet

	tyyppi	julkaisu
2422	Lehti	Allen LV, Jr, Erickson MA, Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1998 ; 55: 1915-1920.
2836	Lehti	Okoka CC, Modwick T, Naira G, Khuspo S, Grady LT. Stability of Hydralazine Hydrochloride in Both Flavored and Nonflavored Extemporaneous Preparations Int J Pharm Compound 2003 ; 7, 4: 313-319.
3168	Lehti	Alexander KS, Pudipeddi M, Parker GA. Stability of hydralazine hydrochloride syrup compounded from tablets. Am J Hosp Pharm 1993 ; 50: 683-686.
4408	Lehti	Polonini H, Loures da Silva S, Neves Cunha C, de Oliveira Ferreira A, Anagnostou K, Dijkers E. Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2020 ;24,3:252-262

Sanakirja

	Verenpaineläkkeet		Injektioneste
	Kauppanimi		Stabilius liuoksessa
	Astia		Molekyyli
	Konsentraatio		Lämpötila
	Säilytys		Vakauden kesto
	biologisesti		ristiriitaisia tietoja
	Viitteet	PVC	Polyvinyylikloridi
	Natriumkloridi 0,9%	?	Ei määritetty
	Päivä		Tekijät, jotka vaikuttavat stabiliuteen
	Liuotin		Glukoosi 5%
	Aiheuttaa		Hajoaminen
	Absorptio		Lisääntynyt stabilius
	Yhteensopivuus		Yhdiste
	Yhteensopiva	Ø	Ei mikään
RL	Ringerlaktaattiliuos		Kemiallinen epävakaus
	yhteensopimaton		Värinvaihto 4 tunnin kuluttua
	Injektionesteisiin käytettävä vesi		Natriumkloridi 0,9% tai Glukoosi 5%
	Värinvaihto		Määrittelemätön yhteensopimattomuus
	Sade 4 tunnin kuluttua		Emulsion epästabiilisuus tunnin kuluttua
	Antotapa		Intravenoosi
	Intravenoosi-infuusio		Intramuskulaarinen
	Viitteet		Oraaliliuos
	Vakaus lääkevalmisteen		Origine
	Apuaine		Lasi
	Jauhe		Suojattava valolta
	Muovipullo		Tabletit
	tunti		Nousu
	Alentunut stabilius		Sanakirja